Hey E
Royal Victoria Infirmary, Newcastle upon Tyne NE1 4LP.
Arch Dis Child Fetal Neonatal Ed. 1999 Nov;81(3):F208-10. doi: 10.1136/fn.81.3.f208.
To investigate the impact of maternal anticonvulsant use on the ability of cord blood to coagulate.
Cord blood prothrombin times were measured, over 15 years in a consecutive series of 137 term babies born to women taking phenobarbitone, phenytoin, and/or carbamazepine while pregnant. The response to parenteral vitamin K was measured in 83 neonates.
Only 14 of the 105 babies born to the mothers who had therapeutic anticonvulsant blood concentrations at birth had a prolonged prothrombin time (outside the 95% reference range). None had an overt bleeding tendency. The abnormality was corrected within 2 hours by 1 mg of parenteral vitamin K, but rapid intravenous prophylaxis produced complications in three infants.
A policy of giving vitamin K throughout the last third of pregnancy to all women being treated with anticonvulsants, as recently recommended, is not justified by the available evidence. The belief that there is a distinct, early form of neonatal vitamin K deficiency that is different from, and more dangerous than, the classic form of the disease, is not supported by a review of the published evidence.
研究母亲使用抗惊厥药物对脐带血凝血能力的影响。
对连续15年中137名足月分娩的婴儿的脐带血凝血酶原时间进行了测量,这些婴儿的母亲在孕期服用苯巴比妥、苯妥英和/或卡马西平。对83名新生儿进行了肌内注射维生素K后的反应测定。
出生时母亲抗惊厥药物血药浓度处于治疗水平的105名婴儿中,只有14名婴儿的凝血酶原时间延长(超出95%参考范围)。无一例有明显出血倾向。1毫克肌内注射维生素K可在2小时内纠正异常,但快速静脉预防在3名婴儿中引发了并发症。
近期建议,对所有接受抗惊厥药物治疗的孕妇在妊娠最后三个月全程给予维生素K,现有证据并不支持这一做法。对已发表证据的回顾并不支持以下观点:存在一种与经典形式不同且更危险的独特早期新生儿维生素K缺乏症。